Merrimack Pharmaceuticals, Inc. (MACK) |
|
12.52 0.15 (1.21%)
|
09-27 16:00 |
|
Open: |
12.41 |
Pre. Close: |
12.37 |
|
High:
|
12.53 |
Low:
|
12.36 |
|
Volume:
|
18,904 |
Market Cap:
|
179(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:20:39 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 14.65 One year: 17.12 |
| Support: |
Support1: 12.2  Support2: 11.98 |
| Resistance: |
Resistance1: 12.55 Resistance2: 14.65 |
| Pivot: |
12.29 |
| Moving Average: |
MA(5): 12.34 MA(20): 12.28
MA(100): 12.26  MA(250): 11.07 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 88.7 %D(3): 75 |
| RSI: |
RSI(14): 63.7 |
| 52-week: |
High: 13.65 Low: 3 |
| Average Vol(K): |
3-Month: 62 (K) 10-Days: 32 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MACK ] has closed above the upper band by 15.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 43.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
12.54 - 12.57 |
12.57 - 12.62 |
|
Low:
|
12.25 - 12.29 |
12.29 - 12.34 |
|
Close:
|
12.44 - 12.51 |
12.51 - 12.59 |
|
Company Description |
|
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Tue, 26 Sep 2023
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) most popular amongst retail investors who own 39% of the shares, institutions hold 33% - Yahoo Finance
Mon, 25 Sep 2023
Seattle cop put on leave after hurling anti-Asian, sexist slurs at neighbor - Yahoo News
Mon, 25 Sep 2023
Fla. Man Charged After Toddler Shoots, Injures Herself With Gun He Allegedly Left Out - Yahoo Entertainment
Tue, 19 Sep 2023
Pancreatic Cancer Battle Boosted by $200M VC Firm - PR Newswire
Fri, 04 Aug 2023
Is SM Energy Company's (NYSE:SM) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - Yahoo Finance
Thu, 03 Aug 2023
Merrimack Reports Second Quarter 2023 Financial Results - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
14 (M) |
| Shares Float |
10 (M) |
|
% Held by Insiders
|
1.2 (%) |
|
% Held by Institutions
|
52.9 (%) |
|
Shares Short
|
1,070 (K) |
|
Shares Short P.Month
|
1,080 (K) |
Stock Financials |
|
EPS
|
-0.11 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.33 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-8.5 |
|
Return on Equity (ttm)
|
-9.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-1 (M) |
|
Levered Free Cash Flow
|
-1 (M) |
Stock Valuations |
|
PE Ratio
|
-113.82 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
9.41 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-121.97 |
Stock Dividends |
|
Dividend
|
0.5 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
3.9% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
